NeuBase Therapeutics, Inc.

Informe acción NasdaqCM:NBSE

Capitalización de mercado: US$1.4m

Salud financiera de hoja de balance de NeuBase Therapeutics

Salud financiera controles de criterios 4/6

NeuBase Therapeutics tiene un patrimonio de los accionistas total de $14.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $21.5M y $7.0M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$13.85m
PatrimonioUS$14.45m
Total pasivoUS$7.01m
Activos totalesUS$21.46m

Actualizaciones recientes sobre salud financiera

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

Aug 26
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Recent updates

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

Aug 26
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

Aug 11

NeuBase Therapeutics promotes Dr. William Mann to President and COO

Jun 29

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23
Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19
We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15
Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($14.2M) de NBSE superan a sus pasivos a corto plazo ($1.9M).

Pasivo a largo plazo: Los activos a corto plazo de NBSE ($14.2M) superan a sus pasivos a largo plazo ($5.1M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: NBSE está libre de deudas.

Reducción de la deuda: NBSE no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Datos insuficientes para determinar si NBSE tiene suficiente cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si NBSE tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera